Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis.
Wiersinga WM, Poppe KG, Effraimidis G.
Lancet Diabetes Endocrinol. 2023 Apr;11(4):282-298. doi: 10.1016/S2213-8587(23)00005-0. Epub 2023 Feb 24.
Hyperthyroidism.
Chaker L, Cooper DS, Walsh JP, Peeters RP.
Lancet. 2024 Feb 24;403(10428):768-780. doi: 10.1016/S0140-6736(23)02016-0. Epub 2024 Jan 23.
Post-ablative hypothyroidism.
Yaqub A, Choudhry MI, Wheaton J, Gress T.
W V Med J. 2011 Mar-Apr;107(2):37-40.
Graves' disease, multinodular goiter and subclinical hyperthyroidism.
Bel Lassen P, Kyrilli A, Lytrivi M, Corvilain B.
Ann Endocrinol (Paris). 2019 Sep;80(4):240-249. doi: 10.1016/j.ando.2018.09.004. Epub 2018 Sep 25.
Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine.
Kang AS, Grant CS, Thompson GB, van Heerden JA.
Surgery. 2002 Dec;132(6):916-23; discussion 923. doi: 10.1067/msy.2002.128691.
Thyroid and menopause.
del Ghianda S, Tonacchera M, Vitti P.
Climacteric. 2014 Jun;17(3):225-34. doi: 10.3109/13697137.2013.838554. Epub 2013 Nov 7.
Animal models of disease: feline hyperthyroidism: an animal model for toxic nodular goiter.
Peterson ME.
J Endocrinol. 2014 Nov;223(2):T97-114. doi: 10.1530/JOE-14-0461.
Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity.
Custro N, Ganci A, Scafidi V.
J Endocrinol Invest. 2003 Feb;26(2):106-10. doi: 10.1007/BF03345136.
Incidence and Risk Factors of Thyroid Malignancy in Patients with Toxic Nodular Goiter.
Mohamed TZ, Sultan AAEA, Tag El-Din M, Mostafa AAE, Nafea MA, Kalmoush AE, Nassar MS, Abdalgaleel MA, Hegab AM, Ibrahim AH, Baheeg M.
Int J Surg Oncol. 2022 May 23;2022:1054297. doi: 10.1155/2022/1054297. eCollection 2022.
Case report: coexistence of primary hyperparathyroidism with giant toxic nodular goiter.
Zhang W, Liu F, Chen K, Wang Y, Dou J, Mu Y, Lyu Z, Zang L.
BMC Endocr Disord. 2022 Aug 9;22(1):200. doi: 10.1186/s12902-022-01117-0.
